Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Top Page
Evaxion Biotech
(NASDAQ:EVAX)
35Underperform
Positive Factors
AI Technology
Evaxion has progressively built not only a set of versatile AI models, but also a strong portfolio of preclinical and clinical candidates allowing for additional value creation.
Partnerships
Merck's decision on option exercise could add to financial strength, as Merck recently increased its stake in Evaxion to nearly 20%.
Negative Factors
Risks
Risks to the Buy rating include partnership, technology, clinical, regulatory, commercial, legal and intellectual property, competition, and dilution.
Evaxion Biotech (EVAX) vs. S&P 500 (SPY)
Market Cap
$2.09M
Dividend YieldN/A
Average Volume (3M)2.51M
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue GrowthN/A
EPS Growth69.19%
CountryUS
Employees49
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)-14.54
Shares Outstanding1,173,211
10 Day Avg. Volume86,689
30 Day Avg. Volume2,514,906
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)152.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.33Price Target Upside536.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Evaxion Biotech Business Overview & Revenue Model
Company DescriptionEvaxion Biotech (EVAX) is a biotechnology company that leverages artificial intelligence (AI) to develop novel immunotherapies for cancer, bacterial diseases, and other indications. The company operates in the pharmaceutical and biotechnology sectors, focusing on the discovery and development of innovative therapies designed to harness the power of the immune system to combat diseases.
How the Company Makes MoneyEvaxion Biotech generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of its AI-driven immunotherapies. Additionally, the company may secure funding through grants and government contracts to support its research and development activities. Evaxion also explores opportunities for revenue through its proprietary platforms by offering them to third parties in exchange for fees or shared intellectual property rights.
Evaxion Biotech Financial Statement Overview
Summary
Evaxion Biotech's financial health is challenged by poor revenue growth history, persistent losses, high financial leverage, and weak cash flows. These factors present significant risks and highlight the company's struggle to achieve financial stability and growth.Income Statement
Evaxion Biotech has shown signs of revenue generation in 2023, but consistently negative net income reflects ongoing financial struggles. The lack of revenue growth prior to 2023 and poor profitability margins indicate significant challenges in achieving sustainable profitability.20
Very Negative
Balance Sheet
The company's balance sheet reveals high financial leverage with a negative stockholders' equity, indicating high risk. The debt-to-equity ratio is concerning, and the equity ratio is negative, reflecting financial instability and a precarious financial position.15
Very Negative
Cash Flow
The cash flow analysis shows consistent cash flow deficits, with negative free cash flow and operating cash flow indicating operational inefficiencies. While there has been some improvement in free cash flow in 2023 compared to 2022, the overall cash flow position remains weak.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 124.48K | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 124.48K | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | EBIT |
| -20.22M | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | EBITDA |
| -14.24M | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | Net Income Common Stockholders |
| -14.73M | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.58M | 5.58M | 13.18M | 32.17M | 5.83M | 9.56M | Total Assets |
| 12.89M | 12.89M | -58.94M | 40.16M | 11.96M | 11.08M | Total Debt |
| 10.87M | 10.87M | 2.25M | 3.69M | 20.00K | 36.00K | Net Debt |
| 5.29M | 5.29M | -10.93M | -28.48M | -5.81M | -9.52M | Total Liabilities |
| 17.62M | 17.62M | 13.72M | 7.73M | 4.93M | 1.72M | Stockholders Equity |
| -4.73M | -4.73M | -72.66M | -50.43M | 7.04M | 9.36M |
| Cash Flow | Free Cash Flow | ||||
| -6.46M | -17.78M | -26.07M | -23.29M | -12.83M | -7.09M | Operating Cash Flow |
| -6.40M | -17.69M | -25.77M | -21.93M | -12.44M | -7.03M | Investing Cash Flow |
| -64.00K | -93.00K | -268.00K | -1.33M | -393.00K | -61.00K | Financing Cash Flow |
| 5.35M | 10.69M | 7.85M | 49.80M | 8.82M | 9.51M |
Evaxion Biotech Technical Analysis
Negative
1.78
Price Trends
3.00
Negative
5.94
Negative
10.53
Negative
Market Momentum
-0.38
Negative
34.92
Neutral
32.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVAX, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 2.12, below the 50-day MA of 3.00, and below the 200-day MA of 10.53, indicating a bearish trend. The MACD of -0.38 indicates Negative momentum. The RSI at 34.92 is Neutral, neither overbought nor oversold. The STOCH value of 32.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVAX.
Evaxion Biotech Risk Analysis
Evaxion Biotech disclosed 117 risk factors in its most recent earnings report. Evaxion Biotech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evaxion Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.86B | 0.03 | -55.16% | 2.48% | 24.39% | -2.90% | |
44 Neutral | $115.22M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $107.89M | ― | -54.21% | ― | -78.55% | -0.92% | |
42 Neutral | $514.33M | ― | -32.06% | ― | ― | 15.34% | |
41 Neutral | $421.49M | ― | -54.15% | ― | ― | ― | |
39 Underperform | $2.45B | ― | 78.99% | ― | 2270.58% | 46.82% | |
35 Underperform | $2.09M | ― | 467.86% | ― | ― | 69.19% |
* Healthcare Sector Average
Performance Comparison
EVAX
Evaxion Biotech
1.78
-13.62
-88.44%
FATE
Fate Therapeutics
0.94
-6.10
-86.65%
ADAP
Adaptimmune Therapeutics
0.45
-1.02
-69.39%
IBRX
ImmunityBio
2.87
-2.36
-45.12%
ALLO
Allogene Therapeutics
1.94
-2.26
-53.81%
CGEM
Cullinan Management
8.79
-6.53
-42.62%
Evaxion Biotech Earnings Call Summary
Earnings Call Date: May 8, 2025 | % Change Since: -87.10% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant achievements, including a transformative agreement with MSD and solid pipeline progress, but also noted challenges with NASDAQ compliance and business development income targets.Highlights
Transformative MSD Agreement
Evaxion signed a significant deal with MSD for EVX-B2 and B3, providing strategic and financial value. Received a $3.2 million upfront payment with potential milestone payments of up to $592 million per product plus royalties on sales.
Solid Pipeline Progress
Released 1-year clinical data from the Phase II trial with EVX-01, showing a 69% overall response rate. Presented proof of concept for mRNA-based B2 vaccine and launched an upgraded version of the EDEN model.
Financial Highlights
Recorded revenue of $3 million for Q3 2024. Executed cost reduction initiatives with lower G&A spending compared to the same period in 2023. Cash and cash equivalents were $4.6 million as of the end of September.
Lowlights
NASDAQ Compliance Challenge
Received a NASDAQ deficiency letter for not meeting the minimum equity requirement. Evaxion is appealing for an additional 180-day exemption to secure compliance.
Business Development Income Shortfall
Unable to meet the $14 million business development income goal for 2024. Certain business development discussions have moved into 2025, impacting financial targets.
Company Guidance
During the Evaxion Q3 2024 earnings call, key guidance was provided, highlighting significant achievements and financial metrics. The transformative deal with MSD, signed in September, was emphasized, with an upfront payment of $3.2 million received in October and potential milestone payments of up to $592 million per product, plus royalties. Revenue for Q3 was $3 million, primarily from the MSD agreement, and the company reported a net loss of $1.9 million, an improvement from the $5.7 million loss in the same quarter last year. Cash and cash equivalents stood at $4.6 million as of September 30, 2024, with the expectation to fund operations until March 2025. The company also discussed its NASDAQ deficiency letter and plans to achieve compliance, aiming for an additional 180-day extension. Evaxion's strategy execution remains strong, with continued progress in R&D and business development, anticipating additional business development income in 2025.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.